Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2016

01-03-2016 | Case Based Review

MDS and GCA: a prognostic dilemma

Authors: Neha G. Narula, Andy Abril

Published in: Clinical Rheumatology | Issue 3/2016

Login to get access

Abstract

A number of autoimmune disorders, such as large vessel vasculitis, have been recognized in patients who have myelodysplastic syndrome (MDS) and myeloproliferative syndrome (MPS). The influence of an autoimmune disorder on the prognosis of patients who have MDS and MPS remains to be determined. We report three cases of myelodysplastic syndrome and large vessel vasculitis seen at our institution and provide a brief literature review of the two disease processes. More studies are needed to determine the pathophysiology of the underlying diseases and whether there truly is a relationship between the disease entities and to discover better markers for disease assessment.
Literature
1.
Berlin NI (1975) Diagnosis and classification of the polycythemias. Semin Hematol 12(4):339–351PubMed
2.
Savage JA, Chang L, Smith CL, Duggan JC (1993) Myelodysplasia, vasculitis and anti neutrophil cytoplasm antibodies. Leuk Lymphoma 9:49–55CrossRef
3.
Landolfi R (1998) Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol 5(5):327–331CrossRefPubMed
4.
Streiff MB, Smith B, Spivak JL (2002) The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members’ practice patterns. Blood 99(4):1144–1149CrossRefPubMed
5.
Espinosa G, Font J, Muñoz-Rodríguez FJ, Cervera R, Ingelmo M (2002) Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship? Clin Rheumatol 21(4):309–313CrossRefPubMed
6.
Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6(4):372–375PubMed
7.
Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29(5):573–582CrossRefPubMed
8.
Hasselbalch HC (2011) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119(14):3219–3225CrossRef
9.
Hasselbalch H (1990) Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 34(4):291–300CrossRefPubMed
10.
Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR (2010) Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 95(7):1216–1220CrossRefPubMedPubMedCentral
11.
Rondeau E, Solal-Celigny P, Dhermy D, Vroclans M, Brousse N, Bernard JF, Boivin P (1983) Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol 53(3):467–475CrossRefPubMed
12.
Hasselbalch H, Nielsen H, Berild D, Kappelgaard E (1985) Circulating immune complexes in myelofibrosis. Scand J Haematol 34(2):177–180CrossRefPubMed
13.
Rizzi R, Pastore D, Liso A, Liuzzi GM, Dalena AM, Specchia G, Ricco R, Liso V (2004) Autoimmune myelofibrosis: report of three cases and review of the literature. Leuk Lymphoma 45(3):561–566CrossRefPubMed
14.
Barosi G, Magrini U, Gale RP (2010) Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis? Leuk Res 34(9):1119–1120CrossRefPubMed
15.
16.
Weyand CM, Liao YJ, Goronzy JJ (2012) The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol 32:259–265CrossRefPubMedPubMedCentral
17.
Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG (1993) Visual prognosis in giant cell arteritis. Ophthalmology 100:550–555CrossRefPubMed
18.
Miller DV, Isotalo PA, Weyand CM, Edwards WD, Aubry MC, Tazelaar HD (2006) Surgical pathology of noninfectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant. Am J Surg Pathol 30:1150–1158CrossRefPubMed
19.
Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, Llorca J (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61:1454–14561CrossRefPubMed
20.
Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therneau TM, Gabriel SE (2011) The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 63:633–639CrossRefPubMedPubMedCentral
21.
Zöller B, Li X, Sundquist J, Sundquist K (2013) Occupational and socio-economic risk factors for giant cell arteritis: a nationwide study based on hospitalizations in Sweden. Scand J Rheumatol 42:487–497CrossRefPubMed
22.
23.
Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM (2008) Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118:1276–1284CrossRefPubMedPubMedCentral
24.
25.
26.
Weyand CM, Goronzy JJ (2014) Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 371(17):1653CrossRefPubMed
27.
Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R (2009) European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318–323CrossRefPubMed
28.
Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, Cimmino M, Gerli R, Catanoso MG, Boiardi L, Cantini F, Klersy C, Hunder GG (2007) Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 146:631–639CrossRefPubMed
29.
Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU, Infliximab-GCA Study Group (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630CrossRefPubMed
30.
Enright H, Miller W (1997) Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 24:483–489CrossRefPubMed
31.
Katsuyama T, Uchida HA, Toma K, Maeda Y, Hirota D, Umebayashi R, Sada KE, Makino H (2014) Large vessel vasculitis with myelodysplastic syndrome. Intern Med 53:63–66CrossRefPubMed
32.
Barrett AJ, Sloand E (2009) Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 94:449–451CrossRefPubMedPubMedCentral
33.
Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, Cacoub P, Saadoun D (2012) Anti TNF-in refractory Takayasu’s arteritis: cases series and review of the literature. Autoimmun Rev 11:678–684CrossRefPubMed
34.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitis. Arthritis Rheum 65:1–11CrossRefPubMed
35.
Belizna C, Subra JF, Henrion D, Ghali A, Renier G, Royer M, Corre YL, Martin L, Voswinkel J, Ifrah N (2013) Prognosis of vasculitis associated myelodysplasia. Autoimmun Rev 10:943–946CrossRef
Metadata
Title
MDS and GCA: a prognostic dilemma
Authors
Neha G. Narula
Andy Abril
Publication date
01-03-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-2993-z

Other articles of this Issue 3/2016

Clinical Rheumatology 3/2016 Go to the issue

Brief Report

The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative

Brief Report

A comparison between ultrasonographic, surgical and histological assessment of tenosynovits in a cohort of idiopathic carpal tunnel syndrome patients

Original Article

Serum C-reactive protein level but not its gene polymorphism is associated with Takayasu arteritis

Brief Report

The descriptive epidemiology of rheumatoid arthritis in Catalonia: a retrospective study using routinely collected data

Case Based Review

Pulmonary Langerhans Histiocytosis: an uncommon cause of interstitial pneumonia in a patient with Sjögren syndrome

Brief Report

Can thyroid volume predict thyroid dysfunction in patients with systemic sclerosis? A prospective cross-sectional study from a tertiary care center in North West India
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits